Finance

Lists
Outlook: 57.1% bullish·0.0% bearish
Go to analysis
VKTX:NASDAQ
Viking Therapeutics Inc
$28.44
-0.25%
(-0.070) 1D
Oct 12, 12:39:16 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VKTX...
Open
$28.23
High
$28.84
Low
$27.91
Mkt. cap
3.62B
Avg. vol.
6.77M
Volume
1.19M
52-wk high
$43.15
52-wk low
$25.77
EPS
-$4.66
Beta
0.66
Shares outstanding
125.99M
No. of employees
65
Open
$28.23
High
$28.84
Low
$27.91
Mkt. cap
3.62B
Avg. vol.
6.77M
Volume
1.19M
52-wk high
$43.15
52-wk low
$25.77
EPS
-$4.66
Beta
0.66
Shares outstanding
125.99M
No. of employees
65
News stories
From web sources and news partners
About Viking Therapeutics Inc
CEOBrian Lian
Employees65
Founded2012
Headquarters-
SectorBiotechnology
Websitevikingtherapeutics.com
Analyst ratings
Based on 17 analysts giving stock ratings to VKTX in the past 3 months
Strong buy
Buy
16
Hold
1
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for VKTX in the last 3 months.
Highest
Current $28.44
$125.00 (+339.52%)
Average
$92.06 (+223.70%)
Lowest
$38.00 (+33.61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Naz Rahman
Maxim Group
Buy
Reiterated
$70.00
+146.1%
10/06/2026
Gregory Renza
Truist Financial
Buy
Maintained
$85.00
+198.9%
10/07/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
$114.00
+300.8%
10/07/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$95.00
+234%
10/06/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$102.00
+258.6%
10/06/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$118.00
+314.9%
09/23/2026
Roger Song
Jefferies
Buy
Maintained
$101.00
+255.1%
09/23/2026
Daniel Brims
Lake Street
Buy
Reiterated
$89.00
+212.9%
09/23/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
$38.00
+33.6%
09/22/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$95.00
+234%
09/22/2026
Jeet Mukherjee
BTIG
Buy
Reiterated
$125.00
+339.5%
09/22/2026
Unknown Analyst
Goldman Sachs
Hold
Maintained
$38.00
+33.6%
09/22/2026
William Wood
B. Riley Securities
Buy
Reiterated
$85.00
+198.9%
09/23/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
09/22/2026
Jay Olson
Oppenheimer
Buy
Reiterated
$120.00
+321.9%
09/22/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
$100.00
+251.6%
08/14/2026
Hardik Parikh
J.P. Morgan
Buy
Maintained
$65.00
+128.6%
08/11/2026
Biren Amin
Piper Sandler
Buy
Maintained
$71.00
+149.6%
07/30/2026
Ryan Deschner
Raymond James
Buy
Maintained
-
-
06/24/2026
Joon Lee
Truist Financial
Buy
Initiated
$83.00
+191.8%
05/27/2026
Unknown Analyst
B. Riley Securities
Buy
Initiated
$85.00
+198.9%
02/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
89.95M
153.46M
150.15M
115.75M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.61M
11.28M
13.98M
16.84M
Operating expense
98.56M
164.74M
164.12M
132.60M
Total operating expenses
98.56M
164.74M
164.12M
132.60M
Operating income
-98.56M
-164.74M
-164.12M
-132.60M
Other non operating income
-
-
-
-
EBT including unusual items
-90.79M
-157.66M
-158.32M
-128.02M
EBT excluding unusual items
-90.80M
-157.70M
-158.32M
-128.05M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-90.79M
-157.66M
-158.32M
-128.02M
Net profit margin
-
-
-
-
Earnings per share
-0.81
-1.38
-1.37
-1.10
Interest and investment income
7.77M
7.04M
5.80M
4.54M
Interest expense
-8.00K
-
-
-
Net interest expenses
7.76M
7.04M
5.80M
4.54M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps